Phar­ma­Mar stock tanks af­ter PhI­II ovar­i­an can­cer study flops

Phar­ma­Mar’s late-stage test of Zep­syre (lur­binecte­din) has flunked the pri­ma­ry end­point on pro­gres­sion-free sur­vival for plat­inum-re­sis­tant ovar­i­an can­cer pa­tients. And the news tanked the Span­ish …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER